Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1985 1
1987 1
2011 1
2012 2
2013 3
2014 6
2015 8
2016 6
2017 11
2018 14
2019 11
2020 14
2021 19
2022 12
2023 13
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

109 results

Results by year

Filters applied: . Clear all
Page 1
[(11) C]PBB3 binding in Abeta(-) or Abeta(+) corticobasal syndrome.
Cselényi Z, Wallin J, Tjerkoski J, Bloth B, Svensson S, Nennesmo I, Sunnemark D, Jelic V, Farde L, Svenningsson P. Cselényi Z, et al. Synapse. 2023 Jul;77(4):e22269. doi: 10.1002/syn.22269. Epub 2023 Apr 30. Synapse. 2023. PMID: 36951466 Free article.
Total binding was higher in all patients compared to the reference group. Similar regional binding profiles of [(11) C]PBB3 in Abeta(+) and Abeta(-) CBS patients were found. Elevated [(11) C]PBB3 binding in pallidum was observed in all CBS patients. Cortical [(11) C …
Total binding was higher in all patients compared to the reference group. Similar regional binding profiles of [(11) C]PBB3 in Abeta( …
Tau PET imaging in neurodegenerative tauopathies-still a challenge.
Leuzy A, Chiotis K, Lemoine L, Gillberg PG, Almkvist O, Rodriguez-Vieitez E, Nordberg A. Leuzy A, et al. Mol Psychiatry. 2019 Aug;24(8):1112-1134. doi: 10.1038/s41380-018-0342-8. Epub 2019 Jan 11. Mol Psychiatry. 2019. PMID: 30635637 Free PMC article. Review.
Investigation of the role of tau pathology in the onset and progression of these disorders is now possible due the recent advent of tau-specific ligands for use with positron emission tomography (PET), including first- (e.g., [(18)F]THK5317, [(18)F]THK5351, [(18)F]AV1451, and [(1 …
Investigation of the role of tau pathology in the onset and progression of these disorders is now possible due the recent advent of tau-spec …
Clinical validity of increased cortical binding of tau ligands of the THK family and PBB3 on PET as biomarkers for Alzheimer's disease in the context of a structured 5-phase development framework.
Chiotis K, Dodich A, Boccardi M, Festari C, Drzezga A, Hansson O, Ossenkoppele R, Frisoni G, Garibotto V, Nordberg A. Chiotis K, et al. Eur J Nucl Med Mol Imaging. 2021 Jul;48(7):2086-2096. doi: 10.1007/s00259-021-05277-4. Epub 2021 Mar 15. Eur J Nucl Med Mol Imaging. 2021. PMID: 33723628 Free PMC article. Review.
The aim of this work was to assess the validation status of tau PET ligands of the THK family and PBB3 as imaging biomarkers for AD, based on the Biomarker Roadmap methodology. ...The level of clinical validity of tau PET ligands of the THK family and PBB3 was asses …
The aim of this work was to assess the validation status of tau PET ligands of the THK family and PBB3 as imaging biomarkers for AD, …
PBB3 imaging in Parkinsonian disorders: Evidence for binding to tau and other proteins.
Perez-Soriano A, Arena JE, Dinelle K, Miao Q, McKenzie J, Neilson N, Puschmann A, Schaffer P, Shinotoh H, Smith-Forrester J, Shahinfard E, Vafai N, Wile D, Wszolek Z, Higuchi M, Sossi V, Stoessl AJ. Perez-Soriano A, et al. Mov Disord. 2017 Jul;32(7):1016-1024. doi: 10.1002/mds.27029. Epub 2017 Jun 1. Mov Disord. 2017. PMID: 28568506
BACKGROUND AND OBJECTIVES: To study selective regional binding for tau pathology in vivo, using PET with [(11) C]PBB3 in PSP patients, and other conditions not typically associated with tauopathy. ...In SNCA duplication carriers, there was a significant increase of [(11) C …
BACKGROUND AND OBJECTIVES: To study selective regional binding for tau pathology in vivo, using PET with [(11) C]PBB3 in PSP patients …
Identification of a major radiometabolite of [11C]PBB3.
Hashimoto H, Kawamura K, Takei M, Igarashi N, Fujishiro T, Shiomi S, Watanabe R, Muto M, Furutsuka K, Ito T, Yamasaki T, Yui J, Nemoto K, Kimura Y, Higuchi M, Zhang MR. Hashimoto H, et al. Nucl Med Biol. 2015 Dec;42(12):905-10. doi: 10.1016/j.nucmedbio.2015.08.006. Epub 2015 Sep 2. Nucl Med Biol. 2015. PMID: 26420569
In this study, we identified the chemical structure of a major radiometabolite of [(11)C]PBB3 and proposed the metabolic pathway of [(11)C]PBB3. METHODS: Carrier-added [(11)C]PBB3 was injected into a mouse for in vivo metabolite analysis. ...CONCLUSION: The m …
In this study, we identified the chemical structure of a major radiometabolite of [(11)C]PBB3 and proposed the metabolic pathway of [ …
PBB3 binding in a patient with corticobasal syndrome.
Perez-Soriano A, Matarazzo M, Vafai N, Shahinfard E, Miao Q, Higuchi M, Sossi V, Stoessl AJ. Perez-Soriano A, et al. Mov Disord. 2018 Aug;33(8):1359-1360. doi: 10.1002/mds.27405. Epub 2018 Jun 22. Mov Disord. 2018. PMID: 29932465 No abstract available.
Tau PET Imaging with [18F]PM-PBB3 in Frontotemporal Dementia with MAPT Mutation.
Su Y, Fu J, Yu J, Zhao Q, Guan Y, Zuo C, Li M, Tan H, Cheng X. Su Y, et al. J Alzheimers Dis. 2020;76(1):149-157. doi: 10.3233/JAD-200287. J Alzheimers Dis. 2020. PMID: 32444551
BACKGROUND: Flortaucipir (AV-1451) and pyridinyl-butadienyl-benzothiazole 3 (PBB3) are newly developed and commonly used positron emission tomography (PET) tracers to detect tau deposition in tauopathies, including frontotemporal dementia (FTD). [18F]PM-PBB3, as a s …
BACKGROUND: Flortaucipir (AV-1451) and pyridinyl-butadienyl-benzothiazole 3 (PBB3) are newly developed and commonly used positron emi …
Quantitative analysis of regional distribution of tau pathology with 11C-PBB3-PET in a clinical setting.
Yousefzadeh-Nowshahr E, Winter G, Bohn P, Kneer K, von Arnim CAF, Otto M, Solbach C, Anderl-Straub S, Polivka D, Fissler P, Strobel J, Kletting P, Riepe MW, Higuchi M, Glatting G, Ludolph A, Beer AJ; Alzheimer’s Disease Neuroimaging Initiative. Yousefzadeh-Nowshahr E, et al. PLoS One. 2022 Apr 11;17(4):e0266906. doi: 10.1371/journal.pone.0266906. eCollection 2022. PLoS One. 2022. PMID: 35404966 Free PMC article.
Among the tau-specific tracers, the application of 11C-pyridinyl-butadienyl-benzothiazole 3 (11C-PBB3) in PET shows high sensitivity to Alzheimer disease (AD)-related tau deposition. The current study investigates the regional tau load in patients within the AD continuum, …
Among the tau-specific tracers, the application of 11C-pyridinyl-butadienyl-benzothiazole 3 (11C-PBB3) in PET shows high sensitivity …
Distinct binding of PET ligands PBB3 and AV-1451 to tau fibril strains in neurodegenerative tauopathies.
Ono M, Sahara N, Kumata K, Ji B, Ni R, Koga S, Dickson DW, Trojanowski JQ, Lee VM, Yoshida M, Hozumi I, Yoshiyama Y, van Swieten JC, Nordberg A, Suhara T, Zhang MR, Higuchi M. Ono M, et al. Brain. 2017 Mar 1;140(3):764-780. doi: 10.1093/brain/aww339. Brain. 2017. PMID: 28087578 Free PMC article.
This was in line with moderate 11C-PBB3 versus faint 18F-AV-1451 autoradiographic labelling of these tissues. ...Our data indicate distinct selectivity of PBB3 compared to AV-1451 for diverse tau fibril strains. This highlights the more robust ability of PBB3 …
This was in line with moderate 11C-PBB3 versus faint 18F-AV-1451 autoradiographic labelling of these tissues. ...Our data indicate di …
109 results

Searches related to "pbb3"